Welltower Inc. (WELL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Welltower Inc. is a leading residential wellness and healthcare infrastructure company operating in the United States, United Kingdom, and Canada. The company manages a portfolio of over 2,000 seniors and wellness housing communities and outpatient medical properties. The company is structured as an umbrella partnership REIT, with substantially all business conducted through Welltower OP LLC.
Key Financial Metrics
| Metric | Q3 2025 (Three Months) | Q3 2024 (Three Months) | YTD 2025 (Nine Months) | YTD 2024 (Nine Months) |
|---|---|---|---|---|
| Total Revenues | $2.69 billion | $2.06 billion | $7.66 billion | $5.74 billion |
| Net Income | $282.2 million | $456.8 million | $844.1 million | $849.1 million |
| Net Income Attributable to Common Stockholders | $280.6 million | $449.8 million | $840.4 million | $831.7 million |
| Diluted EPS | $0.41 | $0.73 | $1.26 | $1.39 |
| Funds From Operations (FFO) | $824.4 million | $635.8 million | $2.42 billion | $1.69 billion |
| Consolidated NOI | $1.11 billion | $843.0 million | $3.10 billion | $2.32 billion |
| Cash and Cash Equivalents | $6.81 billion | $3.51 billion (Dec 31, 2024) | Balance Sheet Item | |
| Total Debt (Carrying Value) | $16.85 billion | $15.50 billion (Dec 31, 2024) | Balance Sheet Item |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 30% year-over-year for the quarter and 33% year-over-year for the nine-month period, driven primarily by acquisitions (including Care UK) and construction conversions.
- Net Income Decline: Net income for the quarter decreased 38% compared to Q3 2024. This decline is largely attributable to a significant one-time gain of $272.3 million in Q3 2024 related to real estate dispositions and acquisitions of controlling interests, which was not repeated in Q3 2025.
- FFO Growth: Funds From Operations (FFO) increased 30% for the quarter and 43% year-to-date, reflecting strong operational performance excluding non-cash depreciation and one-time gains/losses.
- Balance Sheet Expansion: Total assets grew from $51.0 billion to $59.5 billion, and total equity increased from $32.3 billion to $39.0 billion, supported by significant equity issuances and retained earnings.
Guidance, Outlook, and Management Commentary
- Dividend Increase: The Board declared a quarterly dividend of $0.74 per share, a 10.4% increase from the prior quarter.
- Major Acquisitions:
- U.K. Portfolio: In October 2025, the company entered into agreements to acquire a U.K. seniors housing portfolio for approximately £5.2 billion and the HC-One Group portfolio for £1.2 billion.
- Amica Senior Lifestyles: A definitive agreement was announced in March 2025 to acquire a Canadian portfolio for C$4.6 billion, expected to close in early 2026.
- Additional Pipeline: The company has closed or is under contract to close an additional $4.7 billion of seniors housing acquisitions.
- Major Disposition: In August 2025, the company agreed to sell a portfolio of 319 outpatient medical properties for approximately $7.2 billion. The first tranche closed in October 2025. Net proceeds are expected to be approximately $6.0 billion after reinvestment.
- Capital Markets: The company issued $2.7 billion of Canadian-denominated unsecured term loans in October 2025. It also maintained a robust equity distribution program (ATM), selling over 45 million shares in the first nine months of 2025.
- Executive Compensation: In October 2025, the Board approved a new "Ten Year Executive Continuity and Alignment Program" with a preliminary estimated fair value of $1.3 billion, expected to result in approximately $1.0 billion of expense in 2025.
Investor Verification Checklist
- One-Time Gains Impact: Verify the impact of the $272 million gain in Q3 2024 on year-over-year net income comparisons; FFO is a more stable metric for operational performance.
- Outpatient Medical Sale: Monitor the closing timeline and final net proceeds of the $7.2 billion outpatient medical portfolio sale, including the structure of the preferred equity reinvestment.
- U.K. Acquisition Integration: Assess the integration risks and capital requirements for the massive £6.4 billion in U.K. acquisitions announced in October 2025.
- Executive Compensation Expense: Track the recognition of the $1.0 billion expense related to the new executive compensation program in Q4 2025 and subsequent years.
- Debt Maturities: Review the debt maturity schedule, particularly the $1.0 billion unsecured term loan and $250 million Canadian term loan maturing in July 2026.